🚀
Enjoy a 7-Day Free Trial Thru Dec 06, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Altimmune Inc (STU:3G0)
News
Altimmune Inc
STU
:3G0 (USA) Â
€ 8.18
(-0.1%)
Nov 28
P/E:
At Loss
P/B:
4.66
Market Cap:
€ 587.88M
($ 621.41M)
Enterprise V:
€ 457.60M
($ 483.69M)
Volume:
-
Avg Vol (2M):
5.00K
Warning! GuruFocus detected 3 Severe warning signs with 3G0.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
-
Market Cap €:
587.88M
Market Cap $:
621.41M
PE Ratio:
At Loss
Avg Vol (2M):
5.00K
Enterprise Value €:
457.60M
Enterprise Value $:
483.69M
PB Ratio:
4.66
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Altimmune Inc (STU:3G0) Stock News, Headlines & Updates
Altimmune Inc Stock News from GuruFocus
Total 22
1
Nov 26, 2024
Altimmune to Participate at Two Upcoming Investor Conferences
Marketwired
•
7:00am
Nov 15, 2024
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Marketwired
•
10:00am
Nov 14, 2024
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc
GuruFocus News
•
2:14pm
Nov 13, 2024
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments
GuruFocus News
•
1:09am
Q3 2024 Altimmune Inc Earnings Call Transcript
GuruFocus News
•
11:05pm
Nov 12, 2024
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000
GuruFocus News
•
9:19am
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
Marketwired
•
6:00am
Nov 11, 2024
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Marketwired
•
7:00am
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marketwired
•
7:00am
Nov 07, 2024
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Marketwired
•
7:00am
Nov 06, 2024
Altimmune to Participate at Two Upcoming Investor Conferences
Marketwired
•
7:00am
Nov 04, 2024
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Marketwired
•
7:00am
Oct 17, 2024
State Street Corp's Strategic Reduction in Altimmune Inc Holdings
GuruFocus News
•
1:02pm
Oct 16, 2024
Millennium Management LLC Increases Stake in Altimmune Inc
GuruFocus News
•
5:02pm
Oct 15, 2024
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
Marketwired
•
7:00am
Oct 09, 2024
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
GuruFocus News
•
3:35pm
Q2 2024 Altimmune Inc Earnings Call Transcript
GuruFocus News
•
1:38pm
Oct 01, 2024
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Marketwired
•
7:00am
Sep 30, 2024
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Marketwired
•
7:00am
Sep 10, 2024
CORRECTION -- Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Marketwired
•
1:00pm
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Marketwired
•
7:00am
Sep 03, 2024
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Marketwired
•
7:00am
Total 22
1
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news